United Therapeutics Corporation (UTHR): Price and Financial Metrics
UTHR Price/Volume Stats
| Current price | $339.12 | 52-week high | $366.08 |
| Prev. close | $341.11 | 52-week low | $208.62 |
| Day low | $337.52 | Volume | 455,600 |
| Day high | $347.29 | Avg. volume | 489,469 |
| 50-day MA | $335.75 | Dividend yield | N/A |
| 200-day MA | $267.97 | Market Cap | 15.04B |
UTHR Stock Price Chart Interactive Chart >
United Therapeutics Corporation (UTHR) Company Bio
United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.
Latest UTHR News From Around the Web
Below are the latest news stories about UNITED THERAPEUTICS CORP that investors may wish to consider to help them evaluate UTHR as an investment opportunity.
15 Undervalued Defensive Stocks For 2024In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companies that remain relatively stable during economic downturns as opposed to cyclical stocks. Defensive stocks usually outperform […] |
Director Nilda Mesa Sells Shares of United Therapeutics CorpOn December 19, 2023, Director Nilda Mesa sold 605 shares of United Therapeutics Corp (NASDAQ:UTHR), according to a recent SEC Filing. |
Insider Sell: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR)United Therapeutics Corp (NASDAQ:UTHR) has recently witnessed an insider sell that has caught the attention of investors and market analysts. |
Investors in United Therapeutics (NASDAQ:UTHR) have seen stellar returns of 143% over the past five yearsWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... |
Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
UTHR Price Returns
| 1-mo | 5.65% |
| 3-mo | 10.81% |
| 6-mo | 43.25% |
| 1-year | 53.98% |
| 3-year | 69.49% |
| 5-year | 302.76% |
| YTD | 54.22% |
| 2023 | -20.93% |
| 2022 | 28.70% |
| 2021 | 42.35% |
| 2020 | 72.33% |
| 2019 | -19.12% |
Continue Researching UTHR
Want to see what other sources are saying about UNITED THERAPEUTICS Corp's financials and stock price? Try the links below:UNITED THERAPEUTICS Corp (UTHR) Stock Price | Nasdaq
UNITED THERAPEUTICS Corp (UTHR) Stock Quote, History and News - Yahoo Finance
UNITED THERAPEUTICS Corp (UTHR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...